

Poolbeg Pharma plc

Poolbeg to Participate in Key Conferences in March and April 2025

Poolbeg to present at Master Investor Show, BioTrinity & Participate in a Panel Discussion at LSX World Congress

27 March 2025 - [Poolbeg Pharma](#) (AIM: POLB 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that CEO, Jeremy Skillington, will be participating in the following leading industry conferences in March and April 2025:

[Master Investor Show - Business Design Centre, London, UK](#)

Presentation details: 29 March, Showcase Stage (Ground Floor), 1.00pm - 1.10pm
Poolbeg Pharma will be located at Booth M30.

[BioTrinity - Convene, 133 Houndsditch, London, UK](#)

Presentation details: 2 April, Science Spotlight 8 - Rare Disease, 9.30am - 11am
Poolbeg Pharma's presentation will focus on its drug candidate POLB 001, an oral preventative therapy for cancer immunotherapy-induced CRS.

[LSX World Congress - Business Design Centre, London, UK](#)

Panel title: "Thriving Amidst Turbulence: Building Resilience in Life Sciences"
Panel date & time: 30 April, 2pm

If you would like to meet the Poolbeg team at any of the above events, please contact us at ir@poolbegpharma.com.

Enquiries

Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO

+44 (0) 207 183 1499
ir@poolbegpharma.com

Cavendish Capital Markets Ltd (NOMAD & Joint Broker)
Geoff Nash, Camilla Hume, Trisya Jamaludin (Corporate Finance)
Nigel Birks (Life Science Specialist Sales)
Harriet Ward (ECM)

+44 (0) 207 220 0500

Shore Capital Stockbrokers Ltd (Joint Broker)
David Coaten, Harry Davies-Ball (Corporate Advisory)
Malachy McEntyre, Isobel Jones (Corporate Broking)

+44 (0) 207 408 4090

J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist

+353 (0) 1 679 6363

Optimum Strategic Communications
Nick Bastin, Vici Rabbetts, Elena Bates

+44 (0) 208 078 4357
poolbeg@optimumcomms.com

About Poolbeg Pharma plc

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs. Poolbeg comprises a strong and growing portfolio of development assets.

For more information, please go to www.poolbegpharma.com or follow us on [Twitter](#) and [LinkedIn](#) @PoolbegPharma.

Forward-Looking Statements

This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lse.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFLFSDVTIRFIE